Trial Profile

Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Nov 2026 According to a Herantis Pharma media release, company expects to report the Phase 1b biomarker data by mid-January 2026.
16 Mar 2026 According to a Herantis Pharma media release, results from this trial will be presented an oral presentation on Wednesday, 18 March 2026; 14:45 - 15:00 CET at the 20th International Conference on Alzheimer's & Parkinson's Diseases and Related Neurological Disorders (AD/PD 2026), in Denmark from 17-21 March by the CSO - Henri Huttunen
16 Mar 2026 According to a Herantis Pharma media release, primary endpoint (Movement Disorder Society - Unified Parkinsons Disease Rating Scale (MDS-UPDRS) Parts I-III) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com